Klearchos Papas

Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)

High Cell-Density Bioartificial Pancreas Enabled By Miniaturized Wearable Oxygen Generator

�-cell replacement therapy is a promising treatment option for over one million Type 1 Diabetes sufferers in the United States alone, and this research focuses on oxygenation as a way to address key barriers including lacking donor tissue as well as the need for lifelong immunosuppression following transplant. Providing transplanted tissue with oxygen supports health and function and allows for tissue to be densely packed, thereby enabling the use of immunoisolation devices which have previously been prohibitively large (with oxygen, device size can be minimized from the size of a flat screen television to half a credit card). The use of encapsulation devices allows for transplantation without immunosuppression, and will ultimately help to alleviate the burden of lacking donor tissue by enabling the use of � -cells derived from unlimited sources including human stem cells.